YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia
SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, announced promising interim clinical data from an...